Many studies have shown that toxicities of anticancer drugs and their adverse effects are
related to their chemical structure and high molecular weight that may result in a number of …

Immune reactions to small molecular compounds, such as drugs, can cause a variety of
diseases involving the skin, liver, kidney, and lungs. In many drug hypersensitivity reactions …

Modeling clinically relevant tissue responses using cell models poses a significant
challenge for drug development, in particular for drug induced liver injury (DILI). This is …

Diagnosis of drug hypersensitivity is difficult, as an enormous amount of different drugs can
elicit various immune‐mediated diseases with distinct pathomechanism. The lymphocyte …

Up to 5% of all hospital admissions are the result of adverse drug reactions (ADRs).
Identifying those factors which may predispose to ADRs is essential for risk management …

It is generally accepted that there is neither a well-defined nor a consistent link between the
formation of drug− protein adducts and organ toxicity. Because the potential does exist …

To cite this article: Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A,
Campi P, Sanz ML, Castells M, Demoly P, Pichler WJ, for the European Network of Drug …

In an effort to discover small molecule drug candidates with attractive toxicity profiles, the
pharmaceutical industry has predominantly sought compounds that modulate target proteins …

Noncovalent drug presentation leads to the stimulation of immune cells, namely T-cells. The
drug needs two surface molecules (one inert serving as a scaffold, major histocompatibility …

Biological agents‐like cytokines, monoclonal antibodies and fusion proteins are widely used
in anti‐inflammatory and tumour therapy. They are highly efficient in certain diseases, but …